1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Atopic dermatitis (AD) is characterized by skin barrier defects, T helper type 2 cell activation, and increased risk for cutaneous and extracutaneous infections. In clinical trials, dupilumab appeared to decrease rates of skin infections in AD.

          Related collections

          Author and article information

          Journal
          J. Am. Acad. Dermatol.
          Journal of the American Academy of Dermatology
          Elsevier BV
          1097-6787
          0190-9622
          Jan 2018
          : 78
          : 1
          Affiliations
          [1 ] Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
          [2 ] Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Dermatology, Department of Medicine and Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Department of Dermatology, Brown University, Providence, Rhode Island. Electronic address: aaron.drucker@wchospital.ca.
          Article
          S0190-9622(17)32457-X
          10.1016/j.jaad.2017.09.052
          28987493
          9e255704-ba88-40f9-8c34-8fec7426b787
          History

          dupilumab,herpes infections,infections,meta-analysis,atopic dermatitis,atopic eczema

          Comments

          Comment on this article